iifl-logo

Glenmark Pharmaceuticals Ltd Historical Data

Add as a Preferred Source on Google
2,291.4
(0.68%)
Aug 12, 2026|11:54:59 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.

Glenmark Pharmaceuticals Ltd Historical Data

12/07/2026calendar-icon
12/08/2026calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

13-Jul-2026

2,285.9

2,322.92,2642,301.337,1301,65,59,69,387.52,92,536

14-Jul-2026

2,309

2,326.12,2932,305.125,9491,63,50,28,649.23,69,520

15-Jul-2026

2,316

2,318.92,285.62,297.421,1541,13,14,86,261.82,50,669

16-Jul-2026

2,313

2,3132,280.12,286.914,44136,21,06,25878,765

17-Jul-2026

2,287.9

2,287.92,2292,235.519,64179,98,24,7181,27,559

20-Jul-2026

2,235

2,2702,225.32,239.527,3002,05,07,49,666.95,86,534

21-Jul-2026

2,245.8

2,249.32,221.12,242.115,60161,43,03,550.11,22,180

22-Jul-2026

2,229.8

2,229.82,1662,199.935,8122,07,20,87,800.34,52,804

23-Jul-2026

2,185.1

2,241.32,182.82,205.124,1761,25,63,68,329.93,23,031

24-Jul-2026

2,182

2,248.82,1822,19215,21194,21,67,256.82,73,549

27-Jul-2026

2,218

2,2202,183.12,19621,8031,30,63,01,382.13,52,868

28-Jul-2026

2,199.9

2,2082,178.22,184.625,6151,07,39,44,915.63,03,951

29-Jul-2026

2,196.4

2,267.72,186.22,261.734,5101,32,42,59,5312,84,068

30-Jul-2026

2,270.2

2,270.22,182.92,190.326,3421,00,06,47,343.12,30,394

31-Jul-2026

2,207.2

2,256.72,2072,233.922,91783,01,00,271.61,29,929

03-Aug-2026

2,256.4

2,256.42,1622,23063,7792,89,49,54,710.14,12,334

04-Aug-2026

2,238

2,2442,2002,22528,47798,85,14,1072,24,203

05-Aug-2026

2,223

2,263.32,202.22,25927,16786,71,63,6881,40,070

06-Aug-2026

2,270

2,2902,2472,27028,3481,26,31,21,150.12,27,413

07-Aug-2026

2,274.9

2,2892,2562,279.123,25799,64,90,495.91,79,407

10-Aug-2026

2,293

2,297.82,251.32,251.319,41358,59,05,267.793,766

11-Aug-2026

2,265.2

2,2912,2452,27622,00364,65,09,151.41,19,361

Glenmark Pharma.: Related NEWS

Glenmark Pharma Q3 FY26 Profit Rises 16% to ₹403.2 Crore

Revenue from North America increased 24% year on year to ₹970.6 crore, including income from the out licensing of ISB 2001.

31 Jan 2026|02:22 PM
Read More
Top Stocks for Today - 25th September 2025

Here are some of the stocks that may see significant price movement today: Polycab India, Tata Steel, Dalmia Bharat, etc.

25 Sep 2025|06:57 AM
Read More
Top Stocks for Today - 23rd September 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Rail Vikas Nigam, Birla Corp, etc.

23 Sep 2025|07:01 AM
Read More
Glenmark subsidiary gets $700 Million in licensing deal; stock gains

At around 2.19 PM, Glenmark Pharma was trading 2.97% higher at ₹2,112.90 per piece, against the previous close of ₹2,051.90 on NSE.

9 Sep 2025|02:31 PM
Read More
Glenmark Pharma Q1 Net Profit Falls 86% YoY to ₹47 Crore

Operating performance was slightly weaker, with EBITDA dipping 1.4% to ₹580 crore from ₹588.2 crore.

18 Aug 2025|01:03 PM
Read More
Top Stocks for Today - 18th August 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharmaceuticals, Vedanta, Inox Wind, etc.

18 Aug 2025|08:14 AM
Read More
Glenmark Shares Surge 10% After AbbVie Inks Licensing Deal for ISB 2001

The compound is currently in Phase 1B clinical trials, being studied for multiple myeloma, a tough-to-treat form of blood cancer.

11 Jul 2025|09:48 AM
Read More
Top Stocks for Today - 11th July 2025

Here are some of the stocks that may see significant price movement today: Tata Consultancy Services, IREDA, Glenmark Pharma, etc.

11 Jul 2025|07:20 AM
Read More
Top Stocks for Today - 26th May 2025

Here are some of the stocks that may see significant price movement today: Glenmark Pharma, Ashok Leyland, NTPC, etc.

26 May 2025|06:34 AM
Read More
Glenmark Pharma’s cancer drug receive FDA ‘fast track’ status

ISB 2001 is a tri-specific antibody therapeutic for targeting BCMA and CD38 on myeloma cells, as well as CD3 on T cells.

6 May 2025|09:31 AM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.